Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent evidence from in vitro and in vivo studies has demonstrated that aberrant reactivation of the Sonic Hedgehog (SHH) signaling pathway regulates genes that promote cellular proliferation in various human cancer stem cells (CSCs). Therefore, the chemotherapeutic agents that inhibit activation of Gli transcription factors have emerged as promising novel therapeutic drugs for pancreatic cancer. GDC-0449 (Vismodegib), orally administrable molecule belonging to the 2-arylpyridine class, inhibits SHH signaling pathway by blocking the activities of Smoothened. The objectives of this study were to examine the molecular mechanisms by which GDC-0449 regulates human pancreatic CSC characteristics in vitro. METHODOLOGY/PRINCIPAL FINDINGS: GDC-0499 inhibited cell viability and induced apoptosis in three pancreatic cancer cell lines and pancreatic CSCs. This inhibitor also suppressed cell viability, Gli-DNA binding and transcriptional activities, and induced apoptosis through caspase-3 activation and PARP cleavage in pancreatic CSCs. GDC-0449-induced apoptosis in CSCs showed increased Fas expression and decreased expression of PDGFRα. Furthermore, Bcl-2 was down-regulated whereas TRAIL-R1/DR4 and TRAIL-R2/DR5 expression was increased following the treatment of CSCs with GDC-0449. Suppression of both Gli1 plus Gli2 by shRNA mimicked the changes in cell viability, spheroid formation, apoptosis and gene expression observed in GDC-0449-treated pancreatic CSCs. Thus, activated Gli genes repress DRs and Fas expressions, up-regulate the expressions of Bcl-2 and PDGFRα and facilitate cell survival. CONCLUSIONS/SIGNIFICANCE: These data suggest that GDC-0499 can be used for the management of pancreatic cancer by targeting pancreatic CSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894 · cited 1×
“The current standard-of-care therapy, gemcitabine, extends patient survival by only a few weeks [3].”
BackgroundCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · cited 1×
“Activation of the SHH signaling cascade consistently induces Gli family transcription factors (Gli1 and Gli2), hence both Gli genes mRNA [46], expressed in pancreatic cancer cell lines and CSCs, stating potential involvement of SHH signaling in human pancreatic carcinogenesis.”
BackgroundOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · cited 3×
“To identify new therapeutic targets, inhibition of SHH signaling has been attempted in multiple human cancers [11,41,45].”
BackgroundHedgehog signaling in animal development: paradigms and principles
Ingham, P. W., & McMahon, A. P. (2001) · Genes & Development · doi:10.1101/gad.938601 · Cited by 2,985 · cited 1×
“formation during embryogenesis; however, deregulation of this pathway is responsible for several human cancers [8,10,11].”
BackgroundInhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109 · cited 2×
“To identify new therapeutic targets, inhibition of SHH signaling has been attempted in multiple human cancers [11,41,45].”
BackgroundClement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., & Ruiz i Altaba, A. (2007) · Current Biology · doi:10.1016/j.cub.2006.11.033 · Cited by 1,050
A paracrine requirement for hedgehog signalling in cancer
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., Marshall, D., Fu, L., Januario, T., Kallop, D., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961 · cited 1×
“Recent evidence from in vitro and in vivo studies suggests that the Sonic Hedgehog (SHH) signaling pathway [4] is aberrantly reactivated and recognized as one of the mediators in the majority of PCs; therefore, SHH blockade has the potential to prevent disease progression and metastatic spread [5].”
BackgroundWiznerowicz, M., & Trono, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8957-8951.2003 · Cited by 701 · cited 1×
“Transfection of packaging cells and infection of pancreatic CSCs were carried out using standard protocols [50] with some modifications.”
MethodMechanisms of Hedgehog pathway activation in cancer and implications for therapy
Scales, S. J., & de Sauvage, F. J. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.007 · Cited by 650 · cited 3×
“There, Smoothened activates an intracellular cascade that results in activation and nuclear translocation of Gli family transcription factor Gli2 [8].”
Background
Cited by
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 465
Rossi, R., Bellina, F., Lessi, M., & Manzini, C. (2014) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201300922 · Cited by 453
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
The suture provides a niche for mesenchymal stem cells of craniofacial bones
Zhao, H., Feng, J., Ho, T.-V., Grimes, W., Urata, M., & Chai, Y. (2015) · Nature Cell Biology · doi:10.1038/ncb3139 · Cited by 429
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J.-S., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423
Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks
Zhang, J., Tian, X.-J., & Xing, J. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5040041 · Cited by 325
Hedgehog Signaling in the Maintenance of Cancer Stem Cells
Cochrane, C., Szczepny, A., Watkins, D., & Cain, J. (2015) · Cancers · doi:10.3390/cancers7030851 · Cited by 271
Cancer Stem Cell-Specific Scavenger Receptor CD36 Drives Glioblastoma Progression
Hale, J. S., Otvos, B., Sinyuk, M., Alvarado, A. G., Hitomi, M., Stoltz, K., Wu, Q., Flavahan, W., Levison, B., Johansen, M. L., et al. (2014) · Stem Cells · doi:10.1002/stem.1716 · Cited by 258
Cancer stem cells: In the line of fire
Alison, M. R., Lin, W.-R., Lim, S. M. L., & Nicholson, L. J. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.003 · Cited by 225
“GDC-0449 is also effective against CD133 pancreatic CSCs, with enhanced apoptosis appearing to be associated with Fas and Death Receptor (DR) over-expression.(120)”
BackgroundChemical approaches to targeting drug resistance in cancer stem cells
Sotiropoulou, P. A., Christodoulou, M. S., Silvani, A., Herold-Mende, C., & Passarella, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.002 · Cited by 100
DI, C., & ZHAO, Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.2141 · Cited by 72
Metadata
- Authors
- Singh, B. N., Fu, J., Srivastava, R. K., & Shankar, S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-11-08
- Volume
- 6
- Issue
- 11
- Pages
- e27306
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2124111260
- Cited by
- 197
- References
- 46
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.